%0 Journal Article
%T BTN3A is a prognosis marker and a promising target for V¦Ã9V¦Ä2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC)
%A Anne-Sophie Chr¨¦tien
%A Audrey Benyamine
%A C¨¦line Castanier
%A C¨¦line Loncle
%A Daniel Olive
%A Elena Vila-Navarro
%A Etienne Foucher
%A Giuseppe Montalto
%A Jean-Charles Dagorn
%A Juan Iovanna
%A Juan-Luis Blazquez
%A Mauro Modesti
%A Meritxell Gironella
%A Nelson Dusetti
%A Salem Chouaib
%A V¨¦ronique Secq
%J Archive of "Oncoimmunology".
%D 2018
%R 10.1080/2162402X.2017.1372080
%K Immunotherapy
%K Butyrophilin 3 A
%K BTN3A
%K CD277
%K Pancreatic Ductal Adenocarcinoma
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739572/